GSK 3174998Alternative Names: GSK3174998
Latest Information Update: 05 Nov 2015
At a glance
- Originator GlaxoSmithKline
- Class Antineoplastics
- Mechanism of Action OX40 receptor agonists
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
On Fast track
Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.
- New Molecular Entity Yes
Highest Development Phases
- Phase I Solid tumours
Most Recent Events
- 01 Sep 2015 Phase-I clinical trials in Solid tumours (Late-stage disease, Second-line therapy or greater) in USA (IV)
- 17 Aug 2015 GlaxoSmithKline plans a phase I trial for Solid tumours (Late-stage disease, Monotherapy) in USA (NCT02528357)